RT Journal Article
SR Electronic
T1 Pulmonary Artery Pressures and Mortality during VA ECMO: An ELSO Registry Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.08.23293859
DO 10.1101/2023.08.08.23293859
A1 Owyang, Clark G.
A1 Rippon, Brady
A1 Teran, Felipe
A1 Brodie, Daniel
A1 Araos, Joaquin
A1 Burkhoff, Daniel
A1 Kim, Jiwon
A1 Tonna, Joseph E.
YR 2023
UL http://medrxiv.org/content/early/2023/08/15/2023.08.08.23293859.abstract
AB Background Systemic hemodynamics and specific ventilator settings have been shown to predict survival during venoarterial extracorporeal membrane oxygenation (VA ECMO). While these factors are intertwined with right ventricular (RV) function, the independent relationship between RV function and survival during VA ECMO is unknown.Objectives To identify the relationship between RV function with mortality and duration of ECMO support.Methods Cardiac ECMO runs in adults from the Extracorporeal Life Support Organization (ELSO) Registry between 2010 and 2022 were queried. RV function was quantified via pulmonary artery pulse pressure (PAPP) for pre-ECMO and on-ECMO periods. A multivariable model was adjusted for Society for Cardiovascular Angiography and Interventions (SCAI) stage, age, gender, and concurrent clinical data (i.e., pulmonary vasodilators and systemic pulse pressure). The primary outcome was in-hospital mortality.Results A total of 4,442 ECMO runs met inclusion criteria and had documentation of hemodynamic and illness severity variables. The mortality rate was 55%; non-survivors were more likely to be older, have a worse SCAI stage, and have longer pre-ECMO endotracheal intubation times (P < 0.05 for all) than survivors. Improving PAPP from pre-ECMO to on-ECMO time (Δ PAPP) was associated with reduced mortality per 10 mm Hg increase (OR: 0.91 [95% CI: 0.86-0.96]; P=0.002). Increasing on-ECMO PAPP was associated with longer time on ECMO per 10 mm Hg (Beta: 15 [95% CI: 7.7-21]; P<0.001).Conclusions Early improvements in RV function from pre-ECMO values were associated with mortality reduction during cardiac ECMO. Incorporation of Δ PAPP into risk prediction models should be considered.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Tonna is supported by a Career Development Award from the National Institutes of Health/National Heart, Lung, And Blood Institute (K23 HL141596). Dr. Tonna is the Chair-elect of the Registry Committee of the Extracorporeal Life Support Organization (ELSO). Dr. Brodie receives research support from and consults for LivaNova. He has been on the medical advisory boards for Abiomed, Xenios, Medtronic, Inspira and Cellenkos. He is the President-elect of ELSO, the Chair of the Executive Committee of the International ECMO Network (ECMONet), and he writes for UpToDate. None of the funding sources were involved in the design or conduct of the study, collection, management, analysis or interpretation of the data, or preparation, review or approval of the manuscript. No conflicts of interest reported.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective analysis of the ELSO Registry was reviewed and approved by Weill Cornell Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesTo facilitate research reproducibility, replicability, accuracy and transparency, the associated analytic code is available on the Open Science Foundation (OSF) repository, [DOI 10.17605/OSF.IO/82DKM] [https://osf.io/82dkm/]. The data that support the findings of this study are available from ELSO, upon request, to ELSO members; these data were used under license for the current study, and so are not publicly available. Data were de-identified in accordance with Section 164.514 of the Health Insurance Portability and Accountability Act (HIPAA). https://osf.io/82dkm/ ECMOextracorporeal membrane oxygenationELSOExtracorporeal Life Support OrganizationECPRextracorporeal cardiopulmonary resuscitationLVleft ventriclePAPPpulmonary artery pulse pressureSPAPsystolic pulmonary artery pressureDPAPdiastolic pulmonary artery pressurePApulmonary arteryPVRpulmonary vascular resistanceCVPcentral venous pressureRVright ventricleRVDright ventricular dysfunctionVVvenovenousVAvenoarterialCPTCurrent Procedural TerminologyICD-9/10International Classification of Diseases, Ninth Revision/Tenth RevisionMAPmean airway pressureACHDadult congenital heart diseaseMCSmechanical circulatory supportVADventricular assist deviceSCAISociety for Cardiovascular Angiography